The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Karolinska Development AB (publ) owns 65% of Athera Biotechnologies AB. Athera is managed by a core team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization.